Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice

British Journal of Cancer

Volumn 96, Issue 6, 2007, Pages 937-943

  Bruynzeel, A M E ^a   Abou El Hassan, M A ^a,b   Schalkwijk, C ^c   Berkhof, J ^a   Bast, A ^c   Niessen, H W M ^a,d   Van Der Vijgh, W J F ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Anti inflammatory agents; Cardiotoxicity; Doxorubicin; Inflammation; monoHER; N (carboxymethyl) lysine

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ANTIINFLAMMATORY AGENT; DEXAMETHASONE; DOXORUBICIN; KETOPROFEN; MONOXERUTIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; HEART MUSCLE CELL; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; DEXAMETHASONE; DOXORUBICIN; GLYCOSYLATION END PRODUCTS, ADVANCED; HYDROXYETHYLRUTOSIDE; IMMUNOHISTOCHEMISTRY; KETOPROFEN; LYSINE; MALE; MICE; MICE, INBRED BALB C; MYOCYTES, CARDIAC;

EID: 33947354960     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603640     Document Type: Article

References (61)

1. Abou El Hassan MAI, Verheul HMW, Jorna AS, Schalkwijk C, Van Bezu J, Van der Vijgh WJF, Bast A (2003) The new cardioprotector monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro. Br J Cancer 89: 357-362
2. Anderson MM, Heinecke JW (2003) Production of N (epsilon)-(carboxymethyl) lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 52: 2137-2143
3. ε - (carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104: 103-113
4. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286-290
5. Baeuerle PA (1991) The inducible transcription activator NF-κB: regulation by distinct protein subunits. Biochim Biophys Acta 1072: 63-80
6. ε- (carboxymethyl)lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction. Arterioscler Thromb Vasc Biol 26: 2497-2503
7. Baynes JW (1991) Perspectives in diabetes. Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412
8. Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865-872
9. Boulanger E, Wautier MP, Wautier JL, Boval B, Panis Y, Wernert N, Danze PM, Dequiedt P (2002) AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 61: 148-156
10. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632
11. Bruynzeel AME, Mul PNN, Berkhof J, Bast A, Niessen HWM, van der Vijgh WJF (2006) The influence of the time-interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Cancer Chemother Pharmacol 58: 699-702
12. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106: 2827-2835
13. Chen QM, Alexander D, Sun H, Xie L, Lin Y, Terrand J, Morrissy S, Purdom S (2005) Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: induction of antiapoptosis, antioxidant, and detoxification genes. Mol Pharmacol 67: 1861-1873
14. Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Galvez J, Zarzuelo A (2005) In vivo quercitrin anti-inflammatory effects involves release of quercitin, which inhibits inflammation through down-regulation of the NF-κB pathway. Eur J Immunol 35: 584-592
15. Daugherty A, Dunn JL, Rateri DL, Heinecke JW (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94: 437- 444
16. Deepa PR, Varalakshmi P (2005) Biochemical evaluation of the inflammatory changes in cardiac, hepatic and renal tissues of adriamycin-administered rats and the modulatory role of exogenous heparin-derivative treatment. Chem Biol Interact 156: 93-100
17. Deepa PR, Varalakshmi P (2006) Influence of a low-molecular-weight heparin derivative on the nitric oxide levels and apoptotic DNA damage in adriamycin-induced cardiac and renal toxicity. Toxicology 217: 176-183
18. Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP, Baynes JW (1997) The serum concentration of the advanced glycation end-product N epsilon- (carboxymethyl) lysine is increased in uremia. Kidney Int 52: 1064- 1067
19. Dunn JA, Patrick JS, Thorpe SR, Baynes JW (1989) Oxidation of glycated proteins: age-dependent accumulation of Nepsilon-(carboxymethyl) lysine in lens proteins. Biochemistry 28: 9464- 9468
20. Elbl L, Vasova I, Tomaskova I, Jedlicka F, Navratil M, Pospisil Z, Vorlicek J (2006) Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. Neoplasma 53: 174-181
21. Fadillioglu E, Oztas E, Erdogan H, Yagmurca M, Sogut S, Ucar M, irmak MK (2004) Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J Appl Toxicol 24: 47-52
22. Fujihira S, Yamamoto T, Matsumoto M, Yoshizawa K, Oishi Y, Fujii T, Noquchi H, Mori H (1993) The high incidence of atrial thrombosis in mice given doxorubicin. Toxicol Pathol 21: 362-368
23. Gharib MI, Burnett AK (2002) Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 4: 235-242
24. Goto D, Izumi H, Ono M, Okamoto T, Kohno K, Kuwano M (1999) Tubular morphogenensis by genotoxic therapeutic agents that induce NF-κB activation in human vascular endothelial cells. Angiogenesis 2: 345-356
25. Haenen GRMM, Jansen FP, Bast A (1993) The antioxidant properties of five O- (beta-hydroxyethyl) rutosides of the flavonoid mixture Venoruton. Phlebology Suppl. 1: 10-17
26. Hamburger SA, Mc Cay PB (1990) Spin trapping of ibuprofen radicals: evidence that ibuprofen is a hydroxyl radical scavenger. Free Radic Res Commun 9: 337-342
27. Hecker JF (1990) Survival of intravenous chemotherapy infusion sites. Br J Cancer 62: 660-662
28. Horenstein MS, Van der Heide RS, L'Ecuyer TJ (2000) Molecular basis of anthracyclin-induced cardiotoxicity and its prevention. Mol Genet Metab 71: 436-444
29. Hou G, Dick R, Abrams GD, Brewer GJ (2005) Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 146: 299-303
30. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramasamy R, Yan SD, Yan SF, D'Agati V, Schmidt AM (2003) Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 419: 80-88
31. Inchiosa Jr MA, Smith CM (1990) Effects of ibuprofen on doxorubicin toxicity. Res Commun Chem Pathol Pharmacol 67: 63-78
32. Kang BY, Kim SH, Cho D, Kim TS (2005) Inhibition of interleukin-12 production in mouse macrophages via decreased nuclear factor-kappaB DNA binding activity by myricetin, a naturally occurring flavonoid. Arch Pharm Res 28: 274-279
33. Kataoka M, Tonooka K, Ando T, Imai K, Aimoto T (1997) Hydroxyl radical scavenging activity of non-steroidal anti-inflammatory drugs. Free Radic Res 27: 419 -427
34. Kim JS, Jobin C (2005) The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signaling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. Immunology 115: 375-387
35. Koehler L, Hass R, DeWitt DL, Resch K, Goppelt-Struebe M (1990) Glucocorticoid- induced reduction of prostanoid synthesis in TPA-differentiated U937 cells is mainly due to a reduced cyclooxygenase activity. Biochem Pharmacol 40: 1307- 1316
36. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells. J Biol Chem 277: 17179-17187
37. Limat S, Demesmay K, Bernard Y, Deconinck E, Brion A, Sabbah A, Woronoff-Lemsi MC, Cahn JY (2003) Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 14: 277-281
38. Masferrer JL, Seibert K (1994) Regulation of prostaglandin synthesis by glucocorticosteroids. Receptor 4: 25-30
39. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C (1997) Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51: 1170-1181
40. Morteau O (2000) Prostaglandins and inflammation: the cyclooxygenase controversy. Arch Immunol Ther Exp 48: 437- 480
41. ε - (carboxymethyl) lysine formation from amadori product. Biochem Biophys Res Comm 234: 167- 172
42. εε - (carboxymethyl) lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis 144: 41-47
43. Ozmen I (2005) Evaluation of effect of some corticosteroids on glucose-6-phosphate dehydrogenase and comparative study of antioxidant enzyme activities. J Enzyme Inhib Med Chem 20: 19-24
44. Panagiotopoulos S, O'Brien KD, Bucala R, Cooper ME, Jerums G (1998) Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 136: 125-131
45. Read MA, Whitley MZ, Williams AJ, Collins T (1994) NF-κB and IκBα: an inducible regulatory system in endothelial activation. J Exp Med 179: 503-512
46. Schalkwijk CG, Baidoshvili A, Stehouwer CD, van Hinsbergh VW, Niessen HW (2004) Increased accumulation of the glycoxidation product Nepsilon- (carboxymethyl) lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta 1636: 82-89
47. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin Jr AS (1995) Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270: 283-286
48. Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of the glycoxidation product N (epsilon)-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest 99: 457-468
49. Signal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-904
50. Sousa MM, Yan SD, Stern D, Saraiva MJ (2000) Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor κB (NF- κB) activation. Lab Invest 80: 1101-1110
51. Van Acker FA, van Acker SA, Kramer K, Haenen GRMM, Bast A, van der Vijgh WJF (2000) 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res 6: 1337-1341
52. Van Acker SABE, Boven E, Kuiper K, van den Berg DJ, Grimbergen JA, Kramer K, Bast A, van der Vijgh WJF (1997) Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res 3: 1747-1754
53. Van Acker SABE, Towart R, Husken BCP, de Jong J, van der Vijgh WJF, Bast A (1993) The protective effect of Venoruton and its constituents on acute doxorubicin-induced cardiotoxicity. Phlebology Suppl. 1: 31-32
54. Van der Vijgh WJF, Maessen PA, Pinedo HM (1990) Comparative metabolism and pharmacokinetics of doxorubicin and 4′-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice. Cancer Chemother Pharmacol 26: 9-12
55. Vermeulen EG, Niessen HW, Bogels M, Stehouwer CD, Rauwerda JA, v.Hinsbergh VW (2001) Decreased smooth muscle cell / extracellular matrix ratio of femoral artery in patients with atherosclerosis and hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 21: 573 -577
56. Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencweiq M, Muqqia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717
57. Wolf Mb, Baynes JW (2006) The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 1760: 267-271
58. Xu MF, Tang PL, Oian ZM, Ashraf M (2001) Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 68: 889-901
59. Yamada K, Nakamura T, Utsumi H (2006) Enhanced intra-articular free radical reactions in adjuvant arthritis rats. Free Radic Res 40: 455-460
60. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK (1996) The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 98: 1253-1260
61. Zill H, Gunther R, Erbersdobler HF, Folsch UR, Faist V (2001) RAGE expression and AGE-induced MAP-kinase activation in Caco-2 cells. Biochem Biophys Res Commun 288: 1108-1111